Novo Nordisk Ozempic (Semaglutide) injection pen

Ozempic is a prescription medication used to treat type 2 diabetes and for chronic weight management. The brand was developed by Novo Nordisk, a global healthcare company specializing in diabetes care and other serious chronic conditions.

Originally founded in Denmark in 1923, Novo Nordisk has grown into one of the world's most valuable companies. While its primary research and manufacturing hubs remain in Denmark—specifically in Bagsværd and Kalundborg—the scale of Ozempic demand has led to a global supply chain including sites in the United States, France, and Brazil. The brand continues to be owned and managed by Novo Nordisk A/S, with significant voting power held by the Novo Nordisk Foundation through its holding company.